BG106933A - Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses - Google Patents

Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses

Info

Publication number
BG106933A
BG106933A BG106933A BG10693302A BG106933A BG 106933 A BG106933 A BG 106933A BG 106933 A BG106933 A BG 106933A BG 10693302 A BG10693302 A BG 10693302A BG 106933 A BG106933 A BG 106933A
Authority
BG
Bulgaria
Prior art keywords
dihydro
therapeutic uses
amine derivatives
triazine amine
triazine
Prior art date
Application number
BG106933A
Other languages
Bulgarian (bg)
English (en)
Inventor
Gerard Mionet
Daniel Cravo
Liliane Doare
Micheline Kergoat
Didier Mesangeau
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8846333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG106933(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of BG106933A publication Critical patent/BG106933A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG106933A 2000-01-26 2002-07-17 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses BG106933A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000996A FR2804113B1 (fr) 2000-01-26 2000-01-26 Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
PCT/FR2001/000241 WO2001055122A1 (fr) 2000-01-26 2001-01-25 Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique

Publications (1)

Publication Number Publication Date
BG106933A true BG106933A (en) 2003-07-31

Family

ID=8846333

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106933A BG106933A (en) 2000-01-26 2002-07-17 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses

Country Status (36)

Country Link
US (4) US7034021B2 (is)
EP (1) EP1250328B2 (is)
JP (1) JP4926357B2 (is)
KR (1) KR100722438B1 (is)
CN (1) CN1195743C (is)
AP (1) AP2002002578A0 (is)
AR (1) AR027293A1 (is)
AT (1) ATE332294T1 (is)
AU (1) AU782307B2 (is)
BG (1) BG106933A (is)
BR (1) BRPI0107815B8 (is)
CA (1) CA2397636C (is)
CY (1) CY1105344T1 (is)
CZ (1) CZ303445B6 (is)
DE (1) DE60121294T3 (is)
DK (1) DK1250328T4 (is)
EA (1) EA005378B1 (is)
EE (1) EE05003B1 (is)
ES (1) ES2267715T5 (is)
FR (1) FR2804113B1 (is)
HR (1) HRP20020625A2 (is)
HU (1) HU230790B1 (is)
IL (1) IL150530A0 (is)
IS (1) IS6467A (is)
MA (1) MA25650A1 (is)
MX (1) MXPA02007232A (is)
NO (1) NO20023532L (is)
OA (1) OA12165A (is)
PL (1) PL205345B1 (is)
PT (1) PT1250328E (is)
SI (1) SI1250328T2 (is)
SK (1) SK287647B6 (is)
TN (1) TNSN01012A1 (is)
WO (1) WO2001055122A1 (is)
YU (1) YU55602A (is)
ZA (1) ZA200205314B (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
CA2510468C (en) * 2002-12-17 2011-01-04 Hamari Chemicals, Ltd. Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
AU2006259574A1 (en) * 2005-06-14 2006-12-28 Schering Corporation The preparation and use of compounds as aspartyl protease inhibitors
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
DE102007054416A1 (de) * 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
CN102036974B (zh) 2008-05-20 2014-07-23 默沙东公司 利用甘露糖基转移酶抑制剂有效生产异源蛋白质
KR101618198B1 (ko) * 2008-05-23 2016-05-04 뽁셀 에스아에스 3,6-디히드로-1,3,5-트리아진 유도체의 제조방법
EP2332925A4 (en) * 2008-08-25 2014-03-26 Hamari Chemicals Ltd NOVEL DIHYDROTRIAZINE DERIVATIVE
SG171986A1 (en) * 2008-12-12 2011-07-28 Merck Patent Gmbh Combination of insulin with triazine derivatives and its use for treating diabetes
BRPI0922650A2 (pt) * 2008-12-12 2017-07-11 Poxel Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
JP5536869B2 (ja) 2009-03-26 2014-07-02 ポクセル・エスアーエス 優先晶出法を利用したジヒドロ−１，３，５トリアジンラセミ体のエナンチオマー分離のための方法
FR2948026B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948028B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
JP5707489B2 (ja) * 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ １型糖尿病の処置
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
PL2646422T3 (pl) * 2010-12-01 2015-12-31 Poxel Rozdział enancjomerów pochodnych triazyny z zastosowaniem kwasu winowego
RU2658819C2 (ru) * 2016-05-26 2018-06-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет" Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью
FR3068601B1 (fr) 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
SG11202007172YA (en) 2018-06-06 2020-08-28 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2022152138A1 (zh) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途
CN118955413A (zh) * 2024-07-25 2024-11-15 宁夏恒康科技有限公司 一种盐酸伊美格列明的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
US3286366A (en) * 1964-10-26 1966-11-22 Seligman Monroe Apparatus for freeze drying products in small containers
JPS4856692A (is) * 1971-11-19 1973-08-09
JPS4864088A (is) * 1971-12-13 1973-09-05
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
US4246408A (en) * 1979-03-08 1981-01-20 Icn Pharmaceuticals Imidazo[1,2-a]-s-triazine
GR74944B (is) * 1980-07-02 1984-07-12 Merck & Co Inc
US4277602A (en) * 1980-07-02 1981-07-07 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
JPS6141915A (ja) 1984-08-03 1986-02-28 Omron Tateisi Electronics Co 測距装置
DD257010A1 (de) * 1987-01-13 1988-06-01 Berlin Chemie Veb Ergotrope mittel
DE3801113A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Substituierte triazine
IT1244870B (it) * 1990-09-11 1994-09-12 Ministero Dall Uni E Della Ric Composti ammelinici
DE19641692A1 (de) * 1996-10-10 1998-04-23 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine
EP1037886B1 (en) * 1997-12-12 2003-05-02 Abbott Laboratories Triazine angiogenesis inhibitors
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

Also Published As

Publication number Publication date
DK1250328T3 (da) 2006-10-30
CN1404472A (zh) 2003-03-19
SK287647B6 (sk) 2011-05-06
ES2267715T5 (es) 2010-06-10
MA25650A1 (fr) 2002-12-31
US7452883B2 (en) 2008-11-18
CN1195743C (zh) 2005-04-06
BRPI0107815B1 (pt) 2017-08-29
WO2001055122A1 (fr) 2001-08-02
SI1250328T2 (sl) 2010-09-30
US20080108619A1 (en) 2008-05-08
US20030109530A1 (en) 2003-06-12
US20050165022A1 (en) 2005-07-28
ZA200205314B (en) 2005-07-27
MXPA02007232A (es) 2003-10-15
FR2804113B1 (fr) 2004-06-18
BRPI0107815B8 (pt) 2021-05-25
JP2003520858A (ja) 2003-07-08
CY1105344T1 (el) 2010-03-03
HUP0204087A2 (hu) 2003-04-28
PL205345B1 (pl) 2010-04-30
DE60121294T3 (de) 2010-09-23
DE60121294T2 (de) 2007-08-30
OA12165A (fr) 2006-05-08
AU3560301A (en) 2001-08-07
AU782307B2 (en) 2005-07-21
BR0107815A (pt) 2002-10-29
EE200200414A (et) 2003-10-15
US20080108591A1 (en) 2008-05-08
NO20023532L (no) 2002-09-25
PL357191A1 (en) 2004-07-26
JP4926357B2 (ja) 2012-05-09
HU230790B1 (en) 2018-05-02
PT1250328E (pt) 2006-10-31
AR027293A1 (es) 2003-03-19
HRP20020625A2 (en) 2003-10-31
DK1250328T4 (da) 2010-06-28
KR100722438B1 (ko) 2007-05-29
AP2002002578A0 (en) 2002-09-30
US7767676B2 (en) 2010-08-03
EP1250328A1 (fr) 2002-10-23
IL150530A0 (en) 2003-02-12
SI1250328T1 (sl) 2006-10-31
SK9762002A3 (en) 2003-05-02
CZ20022462A3 (cs) 2003-04-16
YU55602A (sh) 2005-03-15
ATE332294T1 (de) 2006-07-15
CA2397636A1 (fr) 2001-08-02
EA200200790A1 (ru) 2003-02-27
EA005378B1 (ru) 2005-02-24
KR20020075395A (ko) 2002-10-04
CA2397636C (fr) 2010-04-06
EP1250328B2 (fr) 2010-04-21
HUP0204087A3 (en) 2006-01-30
ES2267715T3 (es) 2007-03-16
HK1050529A1 (en) 2003-06-27
FR2804113A1 (fr) 2001-07-27
EP1250328B1 (fr) 2006-07-05
DE60121294D1 (de) 2006-08-17
US7034021B2 (en) 2006-04-25
TNSN01012A1 (fr) 2005-11-10
NO20023532D0 (no) 2002-07-24
CZ303445B6 (cs) 2012-09-19
EE05003B1 (et) 2008-04-15
IS6467A (is) 2002-07-11

Similar Documents

Publication Publication Date Title
BG106933A (en) Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
YU72002A (sh) Benzoilpirazoli i njihova primena u ulozi herbicida
NL350075I2 (is)
GEP20074171B (en) N,n'−substituted−1,3−diamino−2−hydroxypropane derivatives
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
MY135841A (en) Novel benzodioxoles
AP2002002637A0 (en) Novel piperazine
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MY132094A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
MY138966A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
GEP20084329B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
BG106585A (en) Kinase inhibitors as therapeutic agents
MXPA05010652A (es) Pirazoles sustituidos.
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
YU78303A (sh) Postupak za dobijanje 1,3-supstituisanih indena i azapolicikličnih jedinjenja sa pripojenim arilom
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
IL140070A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MY136297A (en) Piperazine derivatives having sst1 antagonistic activity
BG105710A (en) 5ht1 antagonists for antidepressant therapy
MXPA05010651A (es) Compuestos de pirazol.
MXPA02009549A (es) Imidazopiridinas triciclicas.
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.